Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
The Covid vaccine battleground gets younger
The FDA has finally confirmed the date of a review of Covid vaccine data in the very young, but has Pfizer/Biontech already won the race?
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
Outside big pharma, life remains tough for listed developers
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
AACR 2022 – A weekend of updates yields few winners
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.
AACR 2022 – Biontech’s cell therapy effort bears fruit at last
But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.
